Circulating microRNA analysis in a prospective co-clinical trial identifies biomarker of response and mechanisms of resistance to regorafenib in colorectal cancer

MicroRNA profiling was performed on baseline bloods using the NanoString nCounter platform in a serial liquid biopsies obtained at baseline in chemo-refractory mCRC patients treated with regorafenib in a phase II clinical trial (PROSPECT-R n=40; NCT03010722). Examination of global miRNA expression profile in liquid biopsy of 40 chemo-refractory mCRC patients treated with regorafenib in a phase II clinical trial (PROSPECT-R n=40; NCT03010722)